NEW YORK, July 9 - Having raised $43 million in a private placement, Signature Bioscience now hopes to complete its transition from early-stage technology company to provider of drug discovery services, CEO Mark McDade told GenomeWeb Monday.
Registering provides access to this and other free content.
Already have an account?Login Now.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.